Caseware UK (AP4) 2024.0.164 2024.0.164 2025-08-312025-08-312026-05-222024-09-01false4939truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 07968894 2024-09-01 2025-08-31 07968894 2023-09-01 2024-08-31 07968894 2025-08-31 07968894 2024-08-31 07968894 c:Director3 2024-09-01 2025-08-31 07968894 c:Director4 2024-09-01 2025-08-31 07968894 d:Buildings d:LongLeaseholdAssets 2024-09-01 2025-08-31 07968894 d:Buildings d:LongLeaseholdAssets 2025-08-31 07968894 d:Buildings d:LongLeaseholdAssets 2024-08-31 07968894 d:PlantMachinery 2024-09-01 2025-08-31 07968894 d:MotorVehicles 2024-09-01 2025-08-31 07968894 d:MotorVehicles 2025-08-31 07968894 d:MotorVehicles 2024-08-31 07968894 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 07968894 d:FurnitureFittings 2024-09-01 2025-08-31 07968894 d:FurnitureFittings 2025-08-31 07968894 d:FurnitureFittings 2024-08-31 07968894 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 07968894 d:ComputerEquipment 2024-09-01 2025-08-31 07968894 d:OtherPropertyPlantEquipment 2024-09-01 2025-08-31 07968894 d:OtherPropertyPlantEquipment 2025-08-31 07968894 d:OtherPropertyPlantEquipment 2024-08-31 07968894 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 07968894 d:OwnedOrFreeholdAssets 2024-09-01 2025-08-31 07968894 d:CurrentFinancialInstruments 2025-08-31 07968894 d:CurrentFinancialInstruments 2024-08-31 07968894 d:CurrentFinancialInstruments 1 2025-08-31 07968894 d:CurrentFinancialInstruments 1 2024-08-31 07968894 d:CurrentFinancialInstruments 5 2025-08-31 07968894 d:CurrentFinancialInstruments 5 2024-08-31 07968894 d:Non-currentFinancialInstruments 2025-08-31 07968894 d:Non-currentFinancialInstruments 2024-08-31 07968894 d:CurrentFinancialInstruments d:WithinOneYear 2025-08-31 07968894 d:CurrentFinancialInstruments d:WithinOneYear 2024-08-31 07968894 d:Non-currentFinancialInstruments d:AfterOneYear 2025-08-31 07968894 d:Non-currentFinancialInstruments d:AfterOneYear 2024-08-31 07968894 d:ShareCapital 2025-08-31 07968894 d:ShareCapital 2024-08-31 07968894 d:RetainedEarningsAccumulatedLosses 2025-08-31 07968894 d:RetainedEarningsAccumulatedLosses 2024-08-31 07968894 c:FRS102 2024-09-01 2025-08-31 07968894 c:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 07968894 c:FullAccounts 2024-09-01 2025-08-31 07968894 c:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 07968894 2 2024-09-01 2025-08-31 07968894 f:PoundSterling 2024-09-01 2025-08-31 iso4217:GBP xbrli:pure

Registered number: 07968894










PRINCE PHARMACY LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 AUGUST 2025

 
PRINCE PHARMACY LIMITED
REGISTERED NUMBER: 07968894

STATEMENT OF FINANCIAL POSITION
AS AT 31 AUGUST 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
1,224,732
674,934

  
1,224,732
674,934

Current assets
  

Stocks
  
849,879
314,298

Debtors: amounts falling due within one year
 5 
1,392,550
408,619

Bank and cash balances
  
309,724
1,315,451

  
2,552,153
2,038,368

Creditors: amounts falling due within one year
 6 
(3,095,522)
(1,895,730)

Net current (liabilities)/assets
  
 
 
(543,369)
 
 
142,638

Total assets less current liabilities
  
681,363
817,572

Creditors: amounts falling due after more than one year
 7 
(538,086)
(338,086)

Provisions for liabilities
  

Deferred tax
  
(69,101)
(125,680)

  
 
 
(69,101)
 
 
(125,680)

Net assets
  
74,176
353,806


Capital and reserves
  

Called up share capital 
  
2
2

Profit and loss account
  
74,174
353,804

  
74,176
353,806


Page 1

 
PRINCE PHARMACY LIMITED
REGISTERED NUMBER: 07968894
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 AUGUST 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 22 May 2026.




Mr Hasan Ukra
Mr Muzar Al-Hakim
Director
Director

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
PRINCE PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

1.


General information

Prince Pharmacy Limited is a private company limited by share capital, incorporated in England and Wales under registration number 07968894. The address of the registered office is The Scalpel, 18 Floor, 52 Lime Street, London, EC3M 7AF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
PRINCE PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

2.Accounting policies (continued)

 
2.3

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
PRINCE PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

2.Accounting policies (continued)

 
2.7

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, .

Depreciation is provided on the following basis:

Long-term leasehold property
-
2%
on cost
Plant and machinery
-
25%
on cost
Motor vehicles
-
25%
reducing balance
Computer equipment
-
25%
on cost
Improvement to properties
-
10%
on cost

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 5

 
PRINCE PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

2.Accounting policies (continued)

 
2.9

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.10

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.11

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.12

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.13

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.


3.


Employees

The average monthly number of employees, including directors, during the year was 49 (2024 - 39).

Page 6

 
PRINCE PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

4.


Tangible fixed assets


Long-term leasehold property
Plant & machinery and fixtures & fittings
Delivery vans & motor vehicles
Improve-      ments to property
Total

£
£
£
£
£



Cost or valuation


At 1 September 2024
135,001
281,983
899,907
95,495
1,412,386


Additions
-
119,452
363,216
483,647
966,315


Disposals
-
-
(293,813)
-
(293,813)



At 31 August 2025

135,001
401,435
969,310
579,142
2,084,888



Depreciation


At 1 September 2024
8,100
223,494
455,678
50,180
737,452


Charge for the year 
2,700
60,617
168,304
50,665
282,286


Disposals
-
-
(159,582)
-
(159,582)



At 31 August 2025

10,800
284,111
464,400
100,845
860,156



Net book value



At 31 August 2025
124,201
117,324
504,910
478,297
1,224,732



At 31 August 2024
126,901
58,489
444,229
45,315
674,934


5.


Debtors

2025
2024
£
£


Amounts owed by connected company
542,464
17,407

Other debtors
258,698
24,280

Rent deposits
341,236
230,185

VAT repayable
42,646
18,869

Prepayments and accrued income
207,506
117,878

1,392,550
408,619


Page 7

 
PRINCE PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025

6.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
2,113,526
1,663,515

Other creditors
631,118
137,299

Other taxation and social security
24,969
15,445

Pension payable
415
-

Wages and salaries
79,534
60,837

Directors' loan account
200,000
-

Accruals and deferred income
45,960
18,634

3,095,522
1,895,730



7.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Amounts owed to parent company
538,086
338,086

538,086
338,086



8.


Controlling party

There was no controlling party.

 
Page 8